Core Viewpoint - A controversial Alzheimer's drug, known as "971," has regained the possibility of being sold after a recent acquisition by Fosun Pharma, which plans to invest approximately 1.412 billion yuan to acquire 51% of Green Valley Pharmaceutical [1][2]. Group 1: Acquisition and Financial Implications - Fosun Pharma's acquisition of Green Valley Pharmaceutical marks the first purchase under the leadership of newly appointed Chairman Chen Yuqing [2]. - The market reacted negatively to the acquisition, with Fosun Pharma's A-shares dropping by 4.22% and Hong Kong shares by 5.81% on December 16 [2]. - The acquisition is expected to have a minimal impact on Fosun Pharma's financial statements in the coming years, as Green Valley will focus on clinical trials post-acquisition [10]. Group 2: Drug Development and Clinical Trials - Fosun Pharma aims to complete post-marketing confirmatory clinical trials for 971, with an optimistic timeline for approval in the first half of 2029 and potential inclusion in medical insurance by 2030 [2][3]. - The estimated cost for domestic Phase III clinical trials is around 685 million yuan, with plans for international multi-center trials if suitable conditions arise [3]. - The target patient population for 971 is approximately 3.56 million, with a projected market penetration rate of 22% [4]. Group 3: Controversies and Efficacy Concerns - The drug's efficacy has been heavily criticized, with notable academic figures questioning its mechanism and clinical trial data [6][7]. - Despite the controversies, there is a significant demand for the drug, with prices reportedly reaching 1,600 to 2,400 yuan, significantly higher than its previous insurance-covered price [8]. - Clinical data from over 800 patients reportedly shows that 971 performs better than a placebo, and there is a growing body of real-world evidence supporting its effectiveness [7]. Group 4: Company Background and Future Prospects - Green Valley Pharmaceutical, founded by Lü Songtao, has faced scrutiny in the past, including allegations of fraudulent claims regarding its products [9][10]. - The company reported revenues of 572 million yuan in 2024, but faced significant losses in the first nine months of 2025 due to the suspension of 971 [10]. - Following the acquisition, Green Valley will operate as a subsidiary of Fosun Pharma, with a focus on completing necessary clinical trials to regain market approval [10].

Core Viewpoint - The recent acquisition of a 51% stake in Green Valley Pharmaceutical by Fosun Pharma aims to revive the controversial Alzheimer's drug, 甘露特钠胶囊 (known as "971"), which had previously faced significant skepticism regarding its efficacy and was halted due to unmet post-marketing clinical trial requirements [1][2][5]. Group 1: Acquisition Details - Fosun Pharma announced an investment of approximately 1.412 billion yuan to acquire a 51% stake in Green Valley Pharmaceutical [1]. - This acquisition marks the first major move by the newly appointed chairman of Fosun Pharma, Chen Yuqing, since taking office in April 2025 [2]. - Following the announcement, Fosun Pharma's stock experienced a decline, with a drop of 4.22% in A-shares and 5.81% in Hong Kong shares on December 16 [2]. Group 2: Clinical Trial Plans - Fosun Pharma plans to conduct post-marketing confirmatory clinical trials for 971, with the goal of obtaining approval by mid-2029 and entering medical insurance by 2030 [2][3]. - The estimated cost for the domestic Phase III clinical trials is around 685 million yuan, with plans for potential international multi-center trials if conditions are favorable [3]. - The clinical trial aims to enroll over 1,900 patients and will adhere to the guidelines set by the National Medical Products Administration [3]. Group 3: Market Potential - The target population for 971 is estimated to be around 3.56 million, with a projected market penetration rate of 22% [4]. - If approved by mid-2029 and included in medical insurance by 2030, the peak sales for 971 are expected to reach approximately 4 billion yuan by 2035 [4]. - In a scenario where the drug is not included in medical insurance, sales in 2030 are anticipated to exceed 1 billion yuan [4]. Group 4: Efficacy Controversies - The efficacy of 971 has been heavily debated, with notable criticisms regarding its mechanism of action and clinical trial data [5][6]. - Despite the controversies, Fosun Pharma maintains confidence in the drug's effectiveness, citing data from over 800 patients showing that 971 outperformed placebo [6]. - The drug's commercial value remains significant, with patients reportedly seeking it at prices significantly higher than previous insurance-covered rates [8]. Group 5: Company Background - Green Valley Pharmaceutical, founded by Lü Songtao in 2018, has faced scrutiny due to past controversies surrounding its products [9][10]. - The company reported revenues of 572 million yuan in 2024, but faced significant losses in 2025 due to the suspension of 971 [10]. - Following the acquisition, Green Valley will operate as a subsidiary of Fosun Pharma, with its future clinical trial efforts being a core focus [10].

Core Viewpoint - Fosun Pharma is optimistic about the potential of the Alzheimer's drug "971," expecting it to complete clinical trials by the end of 2028, receive approval in the first half of 2029, and enter health insurance by 2030, with peak sales projected to reach approximately 4 billion yuan by 2035 [1][2][5]. Group 1: Acquisition and Financial Implications - Fosun Pharma announced plans to invest approximately 1.412 billion yuan to acquire a 51% stake in Green Valley Pharmaceutical, known for the drug "971" [2]. - Following the acquisition announcement, Fosun Pharma's stock fell by 4.22% in A-shares and 5.81% in Hong Kong, indicating market skepticism regarding the decision [3]. - The overall cost for the domestic Phase III clinical trial is estimated to be 685 million yuan, with additional funding planned based on progress [6]. Group 2: Clinical Trial and Regulatory Path - The clinical trial for "971" will be conducted in collaboration with Green Valley Pharmaceutical, with a target of enrolling over 1,900 patients [6][7]. - The expected timeline for completing the registration-confirmatory Phase III clinical trial is by the end of 2028, with a streamlined approval process anticipated to take about 5 to 6 months [6][7]. - The drug's target patient population is estimated to be around 3.56 million, with a market penetration rate projected at 22% [7]. Group 3: Efficacy Controversies - The efficacy of "971" has faced significant scrutiny, with notable criticisms from scholars regarding its mechanism of action and clinical trial data [9][11]. - Despite the controversies, Fosun Pharma maintains confidence in the drug's effectiveness, citing clinical data from over 800 patients that reportedly show better results than placebo [9][12]. - The drug's commercial potential remains strong, with high demand leading to inflated prices in the market, significantly above previous insurance prices [12][13]. Group 4: Company Background and Future Outlook - Green Valley Pharmaceutical, founded by Lü Songtao, has a history of controversial products, but "971" has been a focal point of its business strategy [15][16]. - Following the acquisition, Green Valley will become a subsidiary of Fosun Pharma, with its future operations primarily focused on clinical trials [16]. - The financial impact of Green Valley's operations on Fosun Pharma's overall financials is expected to be minimal in the short term, as the focus will be on completing the necessary clinical work [16].

Core Viewpoint - A controversial Alzheimer's drug, known as "971," has regained the possibility of being marketed after a significant investment by Fosun Pharma, despite ongoing skepticism regarding its efficacy [2][3]. Company Summary - Fosun Pharma announced plans to invest approximately 1.412 billion yuan to acquire a 51% stake in Green Valley (Shanghai) Pharmaceutical Technology Co., known for the drug "971" [3]. - The drug was conditionally approved in China in 2019, marking the first Alzheimer's drug to enter the market in 17 years, with sales of over 2 million boxes expected in 2024 [3][13]. - Due to the failure to complete post-marketing confirmatory clinical trials, the National Medical Products Administration (NMPA) did not approve the drug's reapplication in 2025, leading to its suspension [3][5]. - Fosun Pharma's management expressed confidence in the drug's efficacy and plans to conduct the necessary clinical trials to seek reapproval by 2029, with peak sales projected to reach around 4 billion yuan by 2035 [3][5][8]. Clinical Trial and Regulatory Summary - The company aims to complete the post-marketing confirmatory clinical trials, which are estimated to cost around 685 million yuan, and will involve over 1,900 patients [6][7]. - The trials will assess cognitive and functional outcomes in accordance with international standards, with completion expected by the end of 2028 [7][10]. - Fosun Pharma has already discussed a new plan with the NMPA to meet drug registration requirements [6][8]. Market Reaction and Financial Impact - The market reacted negatively to the acquisition announcement, with Fosun Pharma's stock dropping by 4.22% in A-shares and 5.81% in Hong Kong shares on December 16 [3]. - The estimated target population for the drug is around 3.56 million, with a projected market penetration rate of 22% [8][10]. - If the drug is approved in the first half of 2029 and enters insurance coverage by 2030, peak sales could reach approximately 4 billion yuan; if delayed, sales could still exceed 1 billion yuan in 2030 [8][10]. Controversy and Efficacy Concerns - The drug's efficacy has been heavily criticized, with notable academic figures questioning its mechanism and clinical trial data [9][10]. - Despite the controversies, there is a significant demand for the drug, with prices in the market reportedly reaching 1,600 to 2,400 yuan, significantly higher than its previous insurance price [11][12]. - The ongoing debate about the drug's effectiveness continues to influence investor sentiment and market dynamics [9][10].